The marijuana industry has strong potential
especially after legalization for recreational and medicinal use.
Moreover, the industry is getting benefits of expansion into other
industries like food, beverage, tobacco and cosmetics. Growing
legalization of recreational or medical marijuana is likely to
bolster investorsâ confidence in this industry.
Legalization Considered a Boon for the
Industry
Legalization has long been considered a boon for the marijuana
industry. Canada has become the first major world economy and the
second country after Uruguay to legalize recreational use of
marijuana. Effective Oct 17, 2018, Canadians can legally buy and
consume marijuana.
Cannabis is getting official approval from many U.S. states for
recreational uses, in addition to medical usage. Though pot remains
entirely illegal at the federal level, currently 33 U.S. states
have greenlighted medical use marijuana, while 10 states have
allowed recreational use of marijuana.
Hemp-CBD Market: A New Growth Area
There is growing demand for uses of CBD, a non-psychoactive
ingredient in cannabis, in food, drinks and cosmetics. The Hemp
Business Journal estimated that sales in the hemp-CBD market will
reach to about $1.3 billion by 2022.
The U.S. cannabis companies are still under regulatory
prohibitions. Canadian operators are looking for ways to expand
their reach by mergers and acquisitions. The hemp-CBD market offers
lucrative opportunities for expansion. This is because the 2018
Farm Bill subjects hemp and its derivatives to the agricultural
productsâ category rather than controlled substances.
Strong Market Potential
Research firm Euromonitor has estimated that the American market
for legal marijuana products will reach $20 billion by 2020 from a
mere $5.4 billion in 2015. According to the Arcview Market
Research, the U.S. legal cannabis market is expected to reach $23
billion by 2022. Research firm Cowen projected that the market size
of the U.S. legal cannabis industry will reach $75 billion in by
2030, surpassing the carbonated soft drink market in 2017.
Per a study conducted by Colorado cannabis consulting firm Freedman
& Koski, Illinoisâ annual marijuana market could be between
$1.69 billion and $2.58 billion. Overall, U.S. consumer spending on
legal cannabis is expected to reach $22.2 billion by 2022, while
Canadian spending is estimated to hit $5.9 billion, per a January
report by Arcview Market.
Extremely Volatile Industry
The marijuana industry is considered as extremely volatile. Most of
these companies are in their early stages of development and
characterized as risky for investors. However, this industry had
been providing fabulous returns to investors in 2018 before
legalization in Canada.
Since the industry is in its nascent stage, even a minor negative
may become the cause of major stock price fluctuations. Notably, in
October 2018, the news of supply shortages resulted in panic
selling as investorâs look to offload risky stocks. According to
some industry experts, 5-10% share price volatility daily should
not be considered as unnatural for this industry.
Major Gainers
Major U.S.-listed marijuana companies are likely to gain from the
industryâs early-stage boom. As an evidence of strong demand in the
United States, pot companies have engaged in deals of late.
In the last one year, share prices of major marijuana companies
such as Tilray Inc. TLRY, Cronos Group Inc. CRON, Canopy Growth
Corp. CGC and GW Pharmaceuticals plc GWPH have jumped 213.8%, 175%,
77.8% and 51.7%, respectively. GW Pharmaceuticals carries a Zacks
Rank #2 (Buy). You can see the complete list of todayâs
Zacks #1 Rank (Strong Buy)stocks here.
The chart below shows price performance of four major marijuana
stocks in the last one year.
Breakout Biotech Stocks with Triple-Digit
Profit Potential
The biotech sector is projected to surge beyond $775 billion by
2024 as scientists develop treatments for thousands of diseases.
Theyâre also finding ways to edit the human genome to literally
erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy
Right Now to help investors profit from 7 stocks poised for
outperformance. Our recent biotech recommendations have produced
gains of +98%, +119% and +164% in as little as 1 month. The stocks
in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
GW Pharmaceuticals PLC
(GWPH) : Free Stock Analysis Report
Tilray, Inc. (TLRY) : Free
Stock Analysis Report
Cronos Group Inc. (CRON) :
Free Stock Analysis Report
Canopy Growth Corporation
(CGC) : Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research